Genetic Engineering Groundnut

 

At ICRISAT, we have developed efficient tissue culture and transformation systems for groundnut with high transformation frequency using cotyledon explants forming adventitious shoot buds in different groundnut genotypes and leaflet explants from 2-day in vitro germinated seedlings. The transformation protocol based on cotyledon explants has been optimized for the development of transgenic groundnut capable of producing fertile plants by Agrobacterium tumefaciens -mediated gene transfer that is potentially applicable to a wide range of groundnut genotypes. The protocol uses cotyledon explants from presoaked mature seeds that can produce multiple adventitious buds that are highly amenable to A. tumefaciens infection and result in a large number of transgenic events from a given experiment. In this system, over 85% of the explants produce putative transgenic plants of which large percentage (>55%) show stable gene integration. The status of groundnut transgenics being developed by ICRISAT is listed in the following table.

Constraint
Genes Status
Viruses Indian peanut clump virus (IPCV) Coat protein/ Replicase

T4-T7 plants field-tested in 2002, 2003, 2004, 2005.
5 of 50 promising events selected for resistance

Groundnut rosette-assistor virus (GRAV) Coat Protein 35-T3 events ready for testing in Africa .
Peanut bud necrosis virus (PBNV) Coat Protein
( N-gene )
24 of 48 T2 plants evaluated in contained field tests (2005).
Tobacco streak virus (TSV) Coat Protein 100- T1 events available. Greenhouse evaluation ongoing.
Fungi Aspergillus, Cercospora spp Rice chitinase 9 of 35 T4 events selected under greenhouse testing. Contained field testing planned.
Lox13 [from peanut and soybean] Work initiated in 2006
Abiotic Stress Drought rd29A:DREB1A 10/14 of 44 events at different stages being characterized in dry-down experiments in greenhouse.
Biofortification ß-carotene (pro-vitamin A) oleo : psy (maize)

70 primary events available. Quantification of ß-carotene and identification and selection of T1 events ongoing
30 marker-free events produced.


For further details contact : Drs KK Sharma and Santie de Villiers